Papers

2

Total Citations

15

H-Index

2

About

Yucheng Lu is a clinical researcher whose work focuses on optimizing treatment strategies for locally advanced and high-grade prostate cancer. His research addresses critical gaps in understanding how patient-specific factors, such as initial prostate-specific antigen (iPSA) levels, influence disease progression and therapeutic outcomes. In a highly cited 2020 study (8 citations), Lu demonstrated a counterintuitive finding: patients with high-grade, locally advanced prostate cancer and low iPSA levels paradoxically experienced more rapid disease progression, challenging conventional clinical assumptions. His 2022 propensity score matching analysis (7 citations) provided valuable comparative effectiveness data, showing that robotic-assisted radical prostatectomy may offer distinct advantages over radiotherapy with long-term androgen deprivation therapy for select patients with clinical T3/4 disease. Through rigorous methodological approaches, Lu has helped refine risk stratification and treatment selection in a patient population where optimal management remains debated. His work contributes to the growing body of evidence supporting personalized, risk-adapted approaches in urologic oncology, with implications for both surgical and radiation treatment paradigms.

Research Focus

Key Achievements

2
H-Index
2
Papers
15
Total Citations
8
Avg Citations/Paper
🏆 Most Cited Paper
Association between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer
8 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: National Taiwan University Hospital, National Taiwan University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago